
Rgenta Therapeutics recipient of the Servier’s 2020 LabCentral Golden Ticket
We are committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to provide future generations with a world where quality healthcare is available and accessible to all.
We undertake to provide innovative therapeutic solutions. Driven by a pioneering spirit, we dare, we strive, and we accomplish together.
We prepare for the future by embracing human and environmental dimensions. Our concern for the health and fulfillment of all is our driving force.
Every opportunity to work together contributes to the common good. Whoever we are, wherever we are, we grow and develop by working together, building on one another’s experiences and contributions.
The continuous development of the Group is vital. Whatever challenges we face, we are committed to keeping our promises.
employees in
66 countries
patients treated each day
worldwide
with Servier medicines.
of our turnover,
excluding generics,
is reinvested in R&D.
in revenue comprising €3.2 billion
for brand-name medicines
€1.4 billion for generic medicines.
cardiovascular, cancer, diabetes,
immune-inflammatory
and neuropsychiatric diseases.
Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline
Servier Laboratories Ltd
Sefton House, Sefton Park,
Bells Hill, Stoke Poges SL2 4JS
Tel: 01753 662744
Medical Enquiries: 01753 666409
Fax: 01753 663456